Hakim Djaballah is a Molecular Pharmacologist and Technologist. He obtained his B.S. degree (with honors) from the University of Birmingham, West Midlands, UK, and his Ph.D. degree from the University of Leicester, UK. He began his career at the RW Johnson Pharmaceutical Research Institute followed by positions of increasing responsibilities at various pharmaceutical and biotech companies. He has a significant industrial experience in preclinical drug discovery up to lead compound proof-of-concept. In 2003, he was recruited to the Memorial Sloan-Kettering Cancer Center to set up and direct the newly established HTS Laboratory, a drug discovery laboratory involved in both chemical and RNAi screening with impacts on chemical biology and chemogenomics. His group has developed, validated, and screened several targets in oncology, virology, and infectious diseases with MSK-777, a novel CDC7 inhibitor, as the most advanced compound. His work with Dr. David Abramson led to the repurposing of digoxin for the treatment of retinoblastoma. He was the recipient of the 2007 Robots and Vision User Recognition Award.
Biography Updated on 6 October 2013